IL6 and hepatocellular carcinoma: Epidemiological studies have reported positive associations of prediagnostic circulating levels of biomarkers of inflammation or insulin response such as CRP, IL-6, TNF-α receptor-2, and C-peptide HCC risk (13,14) and CLD mortality (15-17).